Acute Heart Failure: V4 Gold Standard Guide

1. Summary

Acute Heart Failure (AHF) is a medical emergency characterized by the rapid onset or worsening of symptoms and/or signs of HF. [1] It remains a leading cause of hospitalization in patients > 65 years, with a high post-discharge mortality rate (15-20% at 90 days). [2] AHF represents a spectrum of clinical syndromes rather than a single disease entity, ranging from acute decompensation of chronic heart failure (ADHF) to de novo AHF and cardiogenic shock. [3] The central pathophysiology involves a combination of venous congestion (fluid accumulation) and/or reduced cardiac output (hypoperfusion), often triggered by identifiable precipitants such as ischemia, arrhythmias, or hypertensive crises. [4] Early identification using the "Wet vs. Dry" and "Warm vs. Cold" hemodynamic framework is critical for tailoring therapy with diuretics, vasodilators, or inotropic support. [1,5]

2. Key Facts

• The "Flash" Phenomenon: In hypertensive AHF, symptoms arise from fluid redistribution (sympathetic-mediated vasoconstriction) rather than total body volume overload. [6]
• Time is Myocardium: Every hour of delay in IV loop diuretic administration in the ED is associated with a 2% increase in in-hospital mortality (DOROTHY study). [7]
• The "Lethal Diamond" of Shock: In cardiogenic shock, the combination of acidosis, hypothermia, coagulopathy, and hypoperfusion creates a self-perpetuating cycle of myocardial failure. [11]
• Natriuretic Peptide Rule-Out: A BNP less than 100 pg/mL or NT-proBNP less than 300 pg/mL has an incredibly high negative predictive value (> 98%) for ruling out AHF in the acute setting. [9]
• The 25/25 Rule: Roughly 25% of patients with AHF have HF with preserved ejection fraction (HFpEF), and 25% are readmitted within 30 days. [13,14]
• Cardiorenal Crosstalk: Up to 30% of patients develop Type 1 Cardiorenal Syndrome during an AHF admission, which is a major driver of length of stay. [18]

3. Clinical Pearls

The S3 Gallop Pearl: The presence of an S3 gallop is the most specific physical exam finding for AHF (Spec: 99%), representing blood hitting a non-compliant, overfilled ventricle. If you hear it, they have AHF until proven otherwise. [20]

The "Wet vs. Cold" Check: Always feel the hands and feet. A patient can be "Wet" (congested) but if they are also "Cold" (hypoperfused), standard high-dose diuresis may worsen their renal failure. These patients need "unloading" or inotropic support first. [1,11]

The POCUS Utility: Lung ultrasound is significantly more sensitive than chest X-ray (94% vs 75%) for detecting pulmonary edema. Look for "B-lines" (comet tails); > 3 B-lines per rib space is the hallmark of interstitial fluid. [27]

The Hepatojugular Reflux (HJR): A positive HJR (elevation of JVP > 3cm for > 15s during right upper quadrant pressure) is a highly reliable sign of elevated pulmonary capillary wedge pressure (> 15 mmHg). [20]

4. Epidemiology

• Global Burden: AHF is the leading cause of hospitalization in adults > 65 years worldwide, with > 1 million admissions annually in both the US and Europe. [2]
• Hospital Mortality: In-hospital mortality ranges from 4% to 7%, but 1-year mortality approaches 30% in high-risk cohorts. [28]
• Phenotypic Shifts: There is a rising incidence of AHF in the setting of HFpEF, driven by aging populations and the prevalence of obesity, hypertension, and diabetes. [13]
• Racial Disparities: Black Americans have a 2.5-fold higher risk of heart failure and are more likely to present with AHF at a younger age compared to White Americans. [29]
• Economic Impact: Total costs associated with AHF exceed $30 billion annually in the US alone, primarily driven by hospital length of stay and readmissions. [2]

5. 7-Step Molecular Pathophysiology

Step 1: Myocardial Stress & The Sympathetic Surge

In the initial phase of decompensation, a drop in cardiac output or increase in wall stress triggers a massive release of catecholamines (Norepinephrine, Epinephrine). [17] This increases heart rate and contractility (via β1-adrenergic receptors) to maintain BP but at the cost of increased myocardial oxygen demand and direct myocyte toxicity through calcium overload and oxidative stress. Chronic overstimulation leads to receptor downregulation and "catecholamine resistance." [30]

Step 2: RAAS Hyperactivation & The Sodium Trap

Decreased renal perfusion (or perceived decrease via the baroreceptor reflex) activates the Renin-Angiotensin-Aldosterone System. Renin converts Angiotensinogen to Angiotensin I, which is cleaved by ACE to Angiotensin II (AngII). AngII is a potent vasoconstrictor that increases afterload and stimulates Aldosterone release from the adrenal cortex. Aldosterone acts on the ENaC channels in the distal tubule to promote sodium and water retention (increasing preload). [16] This "defensive" mechanism becomes maladaptive, leading to further ventricular stretching and "congestion."

Step 3: The Neprilysin & Natriuretic Peptide Paradox

The heart secretes ANP (Atrial) and BNP (B-type) in response to wall stretch. These peptides promote natriuresis (sodium excretion), vasodilation, and inhibition of RAAS. However, in AHF, these peptides are often "insufficient" either due to downregulation of receptors or rapid degradation by the enzyme Neprilysin. [31] Neprilysin is a neutral endopeptidase that cleaves several vasoactive peptides, including NPs, Bradykinin, and Adrenomedullin. The failure of the "brakes" (NPs) to counteract the "accelerator" (RAAS/SNS) drives the acute congestive state.

Step 4: Cardiorenal Syndrome Type 1 (The Venous Congestion Driver)

Acute cardiac failure leads to reduced arterial flow (forward failure) and, more critically, Venous Congestion (backward failure). Increased central venous pressure (CVP) is transmitted to the renal veins, increasing renal interstitial pressure and intra-abdominal pressure. This reduces the trans-glomerular pressure gradient (P_glomerulus - P_bowmans), leading to a precipitous fall in GFR. [18] This is often more prognostic of renal failure in AHF than low cardiac output.

Step 5: Endothelial Dysfunction & Nitric Oxide Depletion

Systemic inflammation and oxidative stress during AHF reduce the bioavailability of Nitric Oxide (NO). Endothelial cells lose their ability to produce NO, leading to impaired vasodilation and increased stiffness of the systemic vasculature (reduced arterial compliance). This further elevates afterload and promotes fluid shift into the pulmonary interstitium, especially in the "vascular" hypertensive phenotype. [32]

Step 6: Myocyte Stretching & The Biomarker Cascade

As the ventricle dilates to accommodate increased preload, myocyte stretching triggers the release of Troponin (indicating subendocardial ischemia from high wall stress) and ST2/Galectin-3 (markers of fibrosis and inflammation). ST2 is a decoy receptor for IL-33; when high, it blocks the cardio-protective effects of IL-33 signaling, promoting acute remodeling and apoptosis. [21,33]

Step 7: The Congestive Cascade & Lymphatic Failure

Fluid moves from the pulmonary capillaries into the interstitium (Starling equation shift). Initially, the lymphatic system compensates by increasing drainage (up to 10-fold). Once the lymphatic capacity is overwhelmed or CVP becomes high enough to block lymphatic return into the subclavian veins, "Flash" alveolar edema occurs. This leads to severe ventilation-perfusion mismatch (shunting) and hypoxemia. [6,34]

6. Clinical Presentation

The presentation of AHF is typically acute, often occurring over hours (vascular) or days (congestive).

Symptom Cluster

• Dyspnoea: Most common symptom; typically increases with exertion. In the acute setting, it is often sudden (flash) or rapidly progressive. [1]
• Orthopnoea: Highly specific for HF (Spec: 77-88%); patient requires multiple pillows to sleep or must sleep sitting in a chair. It represents the redistribution of fluid from the lower extremities and splanchnic bed to the central circulation when supine. [20]
• Paroxysmal Nocturnal Dyspnoea (PND): Sudden awakening at night (usually 1-2 hours after falling asleep) gasping for air; highly suggestive of pulmonary congestion. PND is more specific than orthopnoea for heart failure. [3]
• Weight Gain: Usually > 2kg in less than 1 week due to fluid retention. This is the most sensitive early marker for an impending decompensation of chronic HF.
• Bendopnoea: Shortness of breath when leaning forward (e.g., tying shoelaces). It indicates high filling pressures and is often seen in advanced HFrEF. [36]
• Reduced Exercise Tolerance: Early sign of declining cardiac reserve.
• Systemic Symptoms: Anorexia, early satiety, and right upper quadrant pain (due to hepatic congestion/Glisson's capsule stretch).

Differential Diagnosis (The "Non-Cardiac" Breathless Patient)

---

7. Special Populations & Phenotypes

1. Peripartum Cardiomyopathy (PPCM)

PPCM is a form of AHF occurring in the last month of pregnancy or first five months postpartum in the absence of other causes. [46]

• The "Two-Hit" Hypothesis: Prolactin-cleaved 16kDa fragment (vasoinhibin) induces endothelial damage and myocyte apoptosis. [47]
• Management: The BOARD regimen (Bromocriptine, Oral HF therapies, Anticoagulation, vAsopressors/inotropes, Diuretics). Bromocriptine (2.5mg BD) inhibits prolactin release and has shown improved LV recovery in the 2017 ESC study. [48]
• Note: ACEi/ARBs/ARNIs and MRAs are strictly contraindicated during pregnancy due to teratogenicity.

2. The Frail Elderly & "The Silver Tsunami"

AHF in patients > 80 years is often characterized by HFpEF, multiple comorbidities, and atypical presentations (e.g., confusion, falls). [49]

• The Polypharmacy Trap: Elderly patients are at high risk for diuretic-induced hypotension and electrolyte derangement.
• Outcome: Readmission rates are 40% higher in the frail cohort, necessitating early geriatric involvement and "hospital-at-home" models. [50]

3. The Obesity Paradox in AHF

While obesity is a risk factor for developing HF, obese patients (BMI 30-35) often have a better short-term prognosis in AHF compared to lean patients. [51]

• Biomarker Warning: BNP and NT-proBNP levels are significantly lower (up to 50%) in obese patients due to increased clearance by adipocytes. Use lower cut-offs to avoid missing the diagnosis. [52]

4. Right Heart Failure (Isolated)

Often secondary to acute PE, RV infarction, or worsening pulmonary hypertension.

• Presentation: Raised JVP, hepatomegaly, and peripheral edema WITHOUT pulmonary crackles.
• Management: Requires careful fluid management (may need "fluid challenge" if RV-preload dependent) vs. diuretics if congested. Inotropes (Milrinone) are preferred as they also reduce pulmonary vascular resistance. [53]

---

8. Physical Exam (with Metrics)

Table data synthesized from JAMA Rational Clinical Examination series and major meta-analyses. [20,35]

High-Yield Exam Steps:

1. Perfusion Check (The "Warm vs. Cold" assessment):
   • Check capillary refill time (normal less than 2s).
   • Assess pulse pressure: A narrow pulse pressure (SBP - DBP less than 25% of SBP) is a strong marker of a low stroke volume. [5]
   • Look for mottled skin (Livedo reticularis) especially over the knees—a sign of critical hypoperfusion.
2. Congestion Check (The "Wet vs. Dry" assessment):
   • JVP: Look for the highest point of pulsation of the internal jugular vein. If not visible, perform the hepatojugular reflux.
   • Auscultation: Listen for the S3 gallop at the apex in the left lateral decubitus position. Listen for lung crackles (rales) which typically start at the bases and move upwards.
3. Mechanical Complication Screen:
   • Specifically listen for the holosystolic murmur of mitral regurgitation at the apex or the harsh systolic murmur of a VSD at the left sternal edge.
   • Check for a friction rub (pericarditis/post-MI).

---

8. Investigations

1. The "Big Three" Diagnostics

• NT-proBNP/BNP: The cornerstone of rule-out. If NT-proBNP less than 300 pg/mL, HF is highly unlikely (NPV > 98%). Age-adjusted cut-offs for NT-proBNP to rule-in are:
  • "Age less than 50: > 450 pg/mL"
  • "Age 50-75: > 900 pg/mL"
  • "Age > 75: > 1800 pg/mL [9]"
  • "Note: Obesity can falsely lower BNP, while Renal failure and Atrial Fibrillation can falsely elevate it."
• 12-Lead ECG: Look for:
  • Ischaemic changes (ST-segment elevation/depression, T-wave inversion).
  • "Left Bundle Branch Block (LBBB): Strongly associated with HFrEF and reduced syncrony."
  • Left Ventricular Hypertrophy (LVH) and "strain" patterns.
  • "Atrial Fibrillation: Both a cause and a consequence of AHF. [1]"
• Chest X-ray (CXR): Look for the classic progression of pulmonary oedema:
  • "Stage 1 (Redistribution): Cephalization of flow (upper lobe diversion)."
  • "Stage 2 (Interstitial Oedema): Kerley B lines (short, horizontal lines at the lung periphery) and peribronchial cuffing."
  • Stage 3 (Alveolar Oedema): "Bat-wing" or "Butterfly" perihilar opacities and pleural effusions (usually bilateral or right-sided). [19]

2. Point-of-Care Ultrasound (POCUS) & Echocardiography

• Lung Ultrasound: The "BLUE" protocol. Presence of > 3 B-lines in 2+ zones bilaterally confirms interstitial syndrome with high sensitivity (94%) and specificity (92%). [27]
• Transthoracic Echocardiogram (TTE):
  • Mandatory within 48h of admission.
  • Assess LVEF (HFrEF vs HFpEF).
  • Check for regional wall motion abnormalities (suggests ACS).
  • Evaluate valvular function (MR, AR, AS).
  • Assess RV function and pulmonary pressures (TAPSE, PASP). [1]

3. Laboratory Evaluation

• Troponin (I or T): Often chronically elevated in HF due to myocyte "leak" from wall stress. A dynamic rise/fall is required to diagnose type 1 MI. [21]
• Renal Profile & Electrolytes:
  • "Creatinine: Baseline is critical for assessing Cardiorenal Syndrome."
  • "Sodium: Hyponatraemia (less than 135 mmol/L) indicates severe RAAS activation and is a powerful predictor of mortality. [8]"
  • "Potassium: Baseline K+ must be known before starting ACEi/MRA or high-dose diuretics."
• Liver Function Tests (LFTs): "Congestive hepatopathy" can lead to elevated bilirubin and transaminases (ALT/AST), while low albumin suggests chronic malnutrition/cachexia.
• Arterial/Venous Blood Gas: Assess for metabolic acidosis and lactate elevation in suspected cardiogenic shock. [11]

8. Investigations: The Diagnostic Triple-Threat

1. Biomarkers: Natriuretic Peptides & Troponin

The diagnostic cornerstone is the assessment of myocardial wall stress via B-type natriuretic peptides.

• NT-proBNP vs. BNP: NT-proBNP is preferred in patients on ARNI (Sacubitril/Valsartan) as Sacubitril inhibits the degradation of BNP but not NT-proBNP. [1]
• The "Rule-Out" Threshold: NT-proBNP less than 300 pg/mL or BNP less than 100 pg/mL has a Negative Predictive Value (NPV) of > 98%. [9]
• The "Rule-In" Age-Adjusted NT-proBNP Cut-offs:
  • "less than 50 years: > 450 pg/mL"
  • "50-75 years: > 900 pg/mL"
  • "> 75 years: > 1800 pg/mL [9]"
• Confounding Factors:
  • "Lowered NPs: Obesity (BMI > 30), flash pulmonary edema (too early for rise), pericardial constriction."
  • "Elevated NPs: Renal failure (reduced clearance), Atrial Fibrillation, advanced age, pulmonary embolism, sepsis."
• High-Sensitivity Troponin: Elevated in > 90% of AHF patients. While a dynamic rise suggests Type 1 MI, a stable elevation reflects ongoing myocyte stress and "leakage" and is strongly prognostic of 1-year mortality. [21]

2. Point-of-Care Ultrasound (POCUS): The Modern Stethoscope

Lung ultrasound is now considered superior to physical exam and CXR for the diagnosis of AHF. [27]

• B-Lines (Comet Tails): Vertical, hyperechoic artifacts arising from the pleural line.
  • Significance: > 3 B-lines in two or more zones bilaterally is the "ultrasonic signature" of interstitial syndrome (AHF, ARDS, or interstitial lung disease).
• Vena Cava (IVC) Assessment:
  • "Dilated IVC (> 2.1 cm) with less than 50% inspiratory collapse: Highly suggestive of high Right Atrial Pressure (RAP) and systemic congestion."
• Focused Cardiac Ultrasound (FoCUS): Assess for gross LV/RV dysfunction, pericardial effusion, and valvular vegetations.

3. Imaging & Electrocardiography

• 12-Lead ECG: Look for "The Big Three":
  1. ACS: ST-elevation or depressions.
  2. Arrhythmia: AF with RVR is a common trigger.
  3. Structural Clues: LBBB, LVH, or pathological Q-waves.
• Chest X-ray: Diagnostic for congestion in 80% of cases. Look for:
  • "Cephalization: Upper lobe diversion of blood flow."
  • "Kerley B Lines: Interlobular septal thickening (short horizontal lines at bases)."
  • Peribronchial Cuffing: "Donut" sign of fluid around the bronchi.
  • "Bat-wing Pattern: Perihilar alveolar edema. [19]"

---

9. Management: The AHF Gold Standard Algorithm

ASCII Management Flowchart (The "CHAMP-Wet-Cold" Protocol)

          [ACUTE SEVERE BREATHLESSNESS / SUSPECTED AHF]
                         |
          +--------------v--------------+
          |    EMERGENCY STABILIZATION  |
          |  (O2 if less than 90%, CPAP/BiPAP)   |
          |  (IV Access, ECG, Monitor)  |
          +--------------+--------------+
                         |
          /--------------+--------------\
   [1. RULE OUT CHAMP]            [2. PHENOTYPE ASSESSMENT]
          |                              |
   +------v------+              /--------+--------\
   | C: ACS      |        [WARM & WET]        [COLD & WET]
   | H: Hypertens|        (Congested)         (Shocked)
   | A: Arrhythm.|              |                  |
   | M: Mech.    |        +-----v-----+      +-----v-----+
   | P: PE       |        | DIURESIS  |      | INOTROPES |
   +------+------+        | (IV Loop) |      | (Dobutam) |
          |               +-----+-----+      +-----+-----+
   +------v------+              |                  |
   | TARGETED    |        +-----v-----+      +-----v-----+
   | THERAPY     |        |VASODILATOR|      |VASOPRESSOR|
   | (e.g. PCI)  |        | (GTN infusion)|  | (Noradren)|
   +-------------+        +-----+-----+      +-----+-----+
                                |                  |
                         /------v------\    /------v------\
                    [DIURETIC SUCCESS?]  [SHOCK RESOLVING?]
                         /           \      /           \
                    [YES]         [NO]  [YES]         [NO]
                      |             |     |             |
                 +----v---+    +----v---+ +---v---+  +---v---+
                 | GDMT   |    | COMBO  | | WEAN  |  | MCS / |
                 | START  |    | DIURESIS| | INO.  |  | ECMO  |
                 +--------+    +--------+ +-------+  +-------+

1. Respiratory Support: Non-Invasive Ventilation (NIV)

• CPAP (Continuous Positive Airway Pressure): 5-10 cmH2O.
• BiPAP (Bilevel): Used if the patient is also hypercapnic (e.g., COPD overlap).
• Mechanism: Increases intrathoracic pressure -> reduces venous return (preload) -> reduces LV transmural wall stress (afterload) -> improves oxygenation and reduces work of breathing. [10]

2. Diuretic Management: The DOSE/ADVOR Protocol

• The Golden Rule: Start IV diuretics within 60 minutes of arrival. [7]
• Dosing (The DOSE Trial): If the patient is diuretic-naive, start with 20-40mg IV Furosemide. If on home diuretics, give 2.5x the home dose as an IV bolus. [7]
• Monitoring (The ADVOR Trial): Adding Acetazolamide (500mg IV) to loop diuretics can improve decongestion efficiency. [43]
• Diuretic Resistance (The CLOROTIC Trial): If urine output less than 100mL/h after 2 hours, double the dose and consider adding a Thiazide (Hydrochlorothiazide 25-50mg) for sequential nephron blockade. [44]

3. Vasoactive Therapy (The Stevenson Profiles)

• Vasodilators (Nitroglycerin/Nitroprusside): Mandatory in the "Hypertensive/Vascular" phenotype (SBP > 140 mmHg). They shift fluid from the lungs back to the systemic circulation.
• Inotropes (Dobutamine/Milrinone): Used ONLY for "Cold and Wet" patients with SBP less than 90 mmHg and signs of organ hypoperfusion.
  • "Caution: Routine use in non-shocked patients increases mortality via arrhythmias and ischemia. [11]"

4. Advanced: Mechanical Circulatory Support (MCS)

In refractory cardiogenic shock (Intermacs 1-2):

• Impella: A microaxial flow pump placed across the aortic valve. It actively unloads the LV, reduces myocardial oxygen demand, and increases cardiac output. [22]
• VA-ECMO (Veno-Arterial Extracorporeal Membrane Oxygenation): Provides full circulatory and respiratory support. However, it increases LV afterload, often requiring "venting" with an Impella (ECMELLA configuration). [54]
• Intra-Aortic Balloon Pump (IABP): Less commonly used now following the IABP-SHOCK II trial (no mortality benefit in post-MI shock), but still used for mechanical complications like acute MR or VSD. [55]

5. Advanced Hemodynamic Monitoring: The PAC Debate

The use of the Pulmonary Artery Catheter (PAC or Swan-Ganz) is controversial following the ESCAPE Trial, which showed no survival benefit for routine PAC use in ADHF. [56]

• Current Indications: Reserved for patients with refractory shock, diagnostic uncertainty between cardiac vs. non-cardiac shock, or those being evaluated for MCS/Transplant. [1]
• Key Parameters:
  • Pulmonary Capillary Wedge Pressure (PCWP): Goal less than 15 mmHg for decongestion.
  • Cardiac Index (CI): Normal > 2.2 L/min/m2.
  • Systemic Vascular Resistance (SVR): Goal 800-1200 dynes/sec/cm-5.
  • Cardiac Power Output (CPO): (MAP x CO) / 451. A CPO less than 0.6 W is the strongest predictor of mortality in cardiogenic shock. [57]

6. Rapid GDMT Titration (The STRONG-HF Protocol)

The STRONG-HF trial (2022) revolutionized the transition from AHF to chronic care. [33]

• The Concept: Rather than "slow and steady" outpatient titration, patients are started on 100% of target doses of the "Four Pillars" (BB, ACEi/ARNI, MRA, SGLT2i) within 2 weeks of discharge.
• Protocol:
  • Week 0 (In-hospital): Start low-dose of all 4 pillars once stable (SBP > 90, off inotropes, improving congestion).
  • Week 2: Up-titrate to 100% target doses.
  • Week 3 & 6: Close monitoring of BP, K+, and NT-proBNP.
• Result: 34% reduction in the risk of 180-day death or HF readmission compared to usual care. [33]

---

10. Refractory AHF & Ultrafiltration

When high-dose diuretics fail (Diuretic Resistance), alternative strategies are required.

1. Sequential Nephron Blockade

• Step 1: Double the dose of IV Loop Diuretic (up to 400-600mg Furosemide/day).
• Step 2: Add a Thiazide (Metolazone 2.5-5mg or IV Chlorothiazide) to block the distal convoluted tubule. [44]
• Step 3: Add Acetazolamide (ADVOR protocol) to block proximal bicarbonate-linked sodium reabsorption. [43]
• Step 4: Low-dose Dopamine (2-3 mcg/kg/min) - though the ROSE-AHF trial showed no benefit for GFR, it may improve urine output in select "Cold" phenotypes. [58]

2. Extracorporeal Ultrafiltration (UF)

UF involves removing isotonic fluid directly from the blood via a peripheral or central venous catheter.

• UNLOAD Trial: Showed UF was superior to diuretics for weight loss and 90-day readmission. [38]
• CARRESS-HF Trial: In patients with AHF and Cardiorenal Syndrome, UF was not superior to stepped pharmacological therapy and was associated with more adverse events (AKI, bleeding). [59]
• Conclusion: UF is a "Tier 3" therapy reserved for patients with truly refractory congestion who fail all pharmacological combinations. [1]

---

11. Cardiorenal Syndrome Type 1: The Deep Dive

Type 1 CRS is defined as acute cardiac dysfunction leading to acute kidney injury (AKI). It occurs in 25-30% of AHF admissions. [18]

The 3-Step Pathophysiology of the "Congestive Kidney"

1. Venous Congestion (The Primary Driver): Elevated central venous pressure (CVP) is transmitted to the renal veins. This increases renal interstitial pressure, leading to kidney swelling within its rigid capsule and compression of the tubules.
2. Reduced Trans-Renal Pressure Gradient: Effective filtration pressure = (Mean Arterial Pressure - Renal Venous Pressure). In AHF, MAP drops and RVP rises, causing the filtration gradient to collapse.
3. RAAS/SNS Overdrive: Sympathetic surge causes afferent arteriolar constriction, while RAAS causes efferent constriction, initially maintaining GFR but ultimately leading to ischemic injury. [18]

Clinical Pearl: The "Pseudo-AKI"

A rise in creatinine (up to 30-50%) during aggressive diuresis is often a benign sign of successful decongestion if the patient is clinically improving. This is termed "Pseudo-AKI" and should not lead to stopping life-saving diuretics. [45]

---

11. Complications: The Multi-Organ Fallout

AHF is rarely confined to the heart; the systemic congestion and hypoperfusion lead to a cascade of organ dysfunction.

1. The Congestive Cascade

• Congestive Hepatopathy ("Shock Liver"): Elevated central venous pressure causes sinusoidal congestion and perivenular necrosis. [60]
  • Lab Signature: Disproportionate rise in direct bilirubin and GGT; ALT/AST may rise acutely in low-flow states.
  • Outcome: Usually resolves with decongestion, but chronic congestion leads to "cardiac cirrhosis."
• Gut Edema & Malabsorption: Venous congestion of the intestinal wall impairs the absorption of oral medications (including loop diuretics), leading to a "vicious cycle" of diuretic resistance. [61]
  • Endotoxemia: Intestinal barrier dysfunction allows translocation of gut bacteria/endotoxins into the systemic circulation, worsening the inflammatory surge of AHF.

2. Arrhythmic & Mechanical

• Atrial Fibrillation (AF): Occurs in > 30% of AHF presentations. The loss of the "atrial kick" reduces cardiac output by 20-25%, often precipitating the decompensation. [15]
• Ventricular Tachycardia (VT): Driven by myocardial stretch, ischemia, and electrolyte shifts (hypokalaemia/hypomagnesaemia from diuretics). VT/VF is the leading cause of sudden death post-AHF discharge. [62]
• Mechanical Complications: Acute mitral regurgitation (due to papillary muscle dysfunction or annular dilation) or VSD (post-MI) can lead to catastrophic pulmonary edema.

3. Iatrogenic Complications

• Diuretic-Induced Alkalosis: Contraction alkalosis and potassium loss can impair respiratory drive and increase the risk of arrhythmias.
• Nosocomial Infections: High risk of VAP (if intubated), CAUTI (if catheterized for UO monitoring), and line-associated sepsis.

---

12. Palliative Care & End-of-Life in AHF

Heart failure has a prognosis often worse than many metastatic cancers, yet palliative care is frequently underutilized. [63]

1. Indicators for Palliative Involvement

• Recurrent hospitalizations (> 3 in 12 months) despite optimal GDMT.
• Persistent NYHA Class IV symptoms (dyspnea at rest).
• Progressive cardiac cachexia (involuntary weight loss).
• Refractory cardiogenic shock where MCS is not appropriate (Bridge to Comfort).

2. Symptom Management

• Dyspnea: Low-dose opioids (Morphine 2.5mg) are the gold standard for refractory breathlessness. They reduce the perception of air hunger without significantly depressing respiratory drive in stable doses. [64]
• Anxiety: Benzodiazepines (Lorazepam) can be used as an adjunct to opioids.
• Congestion: Subcutaneous Furosemide infusions can provide symptom relief for patients who can no longer tolerate IV access or hospital admission.

3. Deactivation of Devices

• Discussion regarding the deactivation of Implantable Cardioverter Defibrillators (ICDs) is mandatory in end-stage AHF to prevent painful, unnecessary shocks during the dying process. [65]

---

13. Prognosis & Risk Stratification

Predictors of In-Hospital Mortality (The GWTG-HF Predictors)

1. BUN > 43 mg/dL: Strongest independent predictor of death. [28]
2. Systolic BP less than 115 mmHg: Indicates poor cardiac reserve.
3. Creatinine > 2.75 mg/dL: Sign of severe cardiorenal dysfunction.
4. Hyponatraemia (less than 134 mmol/L): Reflects profound RAAS activation. [8]

1-Year Outcomes

• The "Vulnerable Phase": The first 90 days after discharge carry a 15% mortality and 30% readmission risk. [14]
• Follow-up: Seeing a specialist within 7 days of discharge reduces 30-day readmissions by 50%.

---

13. Prognosis & Risk Stratification: Beyond the Admission

Prognostication in AHF is essential for determining the intensity of care (ICU vs. ward) and timing of discharge.

1. In-Hospital Mortality Risk: The ADHERE & GWTG-HF Models

• ADHERE Tree: A simple bedside tool using three variables: [66]
  • BUN > 43 mg/dL
  • Systolic BP less than 115 mmHg
  • Creatinine > 2.75 mg/dL
  • Patients with all three have a > 20% in-hospital mortality risk.
• GWTG-HF (Get With The Guidelines): Adds Age, HR, Sodium, and Race/Ethnicity to refine the risk estimate. [28]

2. Post-Discharge Risk: The "Vulnerable Phase"

The 90 days following an AHF admission represent the highest risk period for the patient. [14]

• BIOSTAT-CHF Score: Uses age, BUN, NT-proBNP, hemoglobin, and beta-blocker use to predict 1-year mortality. [67]
• NT-proBNP Reduction: Patients who fail to reduce their NT-proBNP by > 30% during admission have a 3-fold higher risk of readmission. [68]

3. The 5-Point Discharge Checklist

Before a patient with AHF can safely go home, they must meet the following: [1]

1. Clinical Stability: No escalation of diuretics for 24h, off all IV vasoactive therapies for 24-48h.
2. Decongestion: Resolution of B-lines, JVP less than 8cm, and minimal peripheral edema.
3. Optimized GDMT: At least low-dose "Four Pillars" initiated (unless contraindicated).
4. Renal Stability: Stable creatinine/potassium for 48h.
5. Follow-up: Specialist appointment booked within 7 days.

---

14. Landmark Trials Table: The Evidence Base

---

15. Quick Reference: Common Drug Dosing in AHF

---

16. Nursing & Multi-Disciplinary Care

AHF management is a team effort requiring meticulous monitoring and patient education.

1. The Nursing "Vital Four"

• Strict Fluid Balance: Hourly urine output (UO) in critical phase; daily weights (same scale, same time, same clothes) in the ward.
• Oxygen Titration: Maintain SpO2 90-94% (avoid hyperoxia in non-COPD patients as it can cause vasoconstriction).
• Positioning: Orthopneic positioning (sitting upright) to minimize pulmonary venous return.
• Electrolyte Vigilance: Monitoring for "muscle cramps" or "arrhythmias" which may indicate hypokalaemia from diuresis.

2. Discharge & Self-Care Education (FACER)

Before discharge, the multidisciplinary team (Pharmacist, Nurse, Physician) must ensure the patient understands:

• F: Faintness - reporting dizziness.
• A: Ankle swelling - checking daily.
• C: Chest pain - emergency protocols.
• E: Extra weight - > 2kg in 2 days.
• R: Resting breathlessness - immediate review.

---

17. Global Perspectives & Resource-Limited Settings

In many parts of the world, AHF is driven by different etiologies and lacks access to advanced therapies like MCS or ARNIs.

1. Etiological Shifts

• Rheumatic Heart Disease (RHD): Leading cause of AHF in low-middle income countries (LMICs); presents with acute valvular failure/endocarditis. [69]
• Endomyocardial Fibrosis: Specific to tropical regions, causing restrictive AHF phenotypes.
• Chagas Disease: Major cause of AHF in South/Central America, often with severe conduction disease. [70]

2. Management Constraints

• Limited Biomarkers: Where BNP is unavailable, clinical scores (e.g., Boston Criteria) and physical exam (JVP/S3) take precedence.
• Essential Medicines: Focus on affordable GDMT (Generic ACEi, Beta-blockers, and Spironolactone).
• Point-of-Care Echocardiography: Expanding the use of handheld devices for rapid triage in rural clinics.

---

18. Layperson Explanation: The "Broken Pump" Analogy

What is happening?

Think of your heart as a pump that moves water through the pipes (blood vessels) of your house. If the pump gets old or clogged, the water doesn't move fast enough. It starts to back up in the pipes. In your body, the "pipes" lead to your lungs and your legs.

When water backs up in your lungs, it feels like you're trying to breathe through a wet sponge. This is why you feel short of breath and why it’s harder to breathe when you lie flat (gravity makes the water spread out across your lungs).

How do we fix it?

1. The Drainage: We use "water tablets" (diuretics) to help your kidneys flush the extra fluid out of your system. You will notice you are peeing much more than usual—this is a good sign!
2. The Breathing Mask: We may use a tight-fitting mask (CPAP) that uses air pressure to push the fluid out of your air sacs, making it easier for you to get oxygen.
3. The Shield: Once you are feeling better, we start you on four specific medicines. Think of these as a "protective shield" for your heart. They help the pump work more efficiently and prevent it from getting weaker over time.

What should you watch for at home?

Remember the "FACER" signs:

• Faintness or severe dizziness.
• Ankle swelling that is getting worse.
• Chest pain or a racing heart.
• Extra weight (more than 2kg in 2 days).
• Resting breathlessness.

---

16. Single Best Answer (SBA) Questions: Clinical Mastery

Question 1: The Hypertensive Presentation

A 68-year-old female presents to the ED with "flash" pulmonary edema. BP is 220/120 mmHg, HR 125 bpm, and SpO2 82% on room air. She is sitting upright and gasping. Which hemodynamic mechanism is primarily responsible for her acute presentation?

• A) Severe total body sodium and water overload
• B) Sympathetic-mediated fluid redistribution to the pulmonary bed
• C) Acute rupture of the mitral valve chordae
• D) Chronic RAAS activation and secondary hyperaldosteronism
• E) Right ventricular failure leading to venous congestion
• Answer: B. Hypertensive AHF (Flash Pulmonary Edema) is driven by sudden sympathetic-mediated vasoconstriction which shifts fluid from the splanchnic and systemic venous beds into the pulmonary circulation. It is a "redistribution" problem, not necessarily a "total volume" problem. [6]

Question 2: The Cardiorenal Conundrum

A 72-year-old male is being treated for AHF with IV Furosemide 80mg BD. On day 3, his creatinine has risen from 100 µmol/L to 145 µmol/L. His JVP has dropped from 10cm to 4cm, and his B-lines on POCUS have resolved. What is the most appropriate next step?

• A) Stop diuretics and start IV fluid boluses for AKI
• B) Reduce diuretic dose and check for urinary sodium
• C) Continue current management as this represents successful decongestion
• D) Perform an urgent renal artery doppler
• E) Request an urgent nephrology consult for ultrafiltration
• Answer: C. This is "Pseudo-AKI." A moderate rise in creatinine (up to 50%) during successful decongestion (as evidenced by falling JVP and resolving B-lines) is actually associated with better long-term outcomes than "persistent congestion" with a stable creatinine. [45]

Question 3: The Biomarker Trap

A 55-year-old male with a BMI of 42 presents with progressive dyspnea. His NT-proBNP is 410 pg/mL. Which of the following is the most accurate interpretation of this result?

• A) AHF is ruled out as the level is less than 450 pg/mL
• B) The level is falsely elevated due to his obesity
• C) The level is likely falsely lowered and AHF should still be considered
• D) NT-proBNP is only useful for ruling out, not ruling in HF
• E) NT-proBNP is a substrate for Neprilysin and cannot be used
• Answer: C. Obesity (BMI > 30) is associated with significantly lower levels of natriuretic peptides (BNP and NT-proBNP) for a given degree of heart failure. A "gray zone" result in an obese patient should be treated with high suspicion for AHF. [52]

Question 4: The 2-Hour Diuretic Check

According to the 2021 ESC Guidelines, what is the most appropriate action if a patient with AHF has a spot urinary sodium of 35 mmol/L two hours after their first dose of IV Furosemide?

• A) Continue the same dose every 12 hours
• B) Double the dose of IV Furosemide immediately
• C) Switch to a continuous infusion of Furosemide
• D) Add 250ml of Normal Saline to improve renal perfusion
• E) Prepare the patient for urgent ultrafiltration
• Answer: B. An adequate response to a loop diuretic is defined as a spot urinary sodium > 50-70 mmol/L at 2 hours. A level of 35 mmol/L indicates diuretic resistance; the dose should be doubled immediately. [1]

Question 5: The Post-Discharge Strategy

A 60-year-old male is ready for discharge following an AHF admission. He is on low-dose Ramipril and Bisoprolol. According to the STRONG-HF trial, what is the optimal follow-up and titration strategy?

• A) Review in clinic in 3 months for gradual titration
• B) Achieve 100% of target GDMT doses within 2 weeks of discharge
• C) Only titrate once the NT-proBNP has normalized
• D) Titrate meds one by one every 4 weeks to ensure tolerance
• E) Stop all meds if the LVEF improves to > 50%
• Answer: B. The STRONG-HF trial demonstrated that a strategy of "high-intensity" care—achieving target doses of the four pillars within 2 weeks of discharge—significantly reduces 180-day mortality and HF readmissions. [33]

Question 6: The "Cold and Wet" Management

A 70-year-old male presents with BP 85/55 mmHg, cold extremities, and bibasal crackles. NT-proBNP is 15,000 pg/mL. Which of the following is the most appropriate initial pharmacological choice for hemodynamic support?

• A) High-dose IV Nitroglycerin infusion
• B) IV Metoprolol 5mg bolus
• C) IV Dobutamine infusion
• D) IV Furosemide 120mg bolus
• E) Oral Spironolactone 25mg
• Answer: C. This patient is in the "Cold and Wet" profile (Cardiogenic Shock). They require inotropic support (Dobutamine or Milrinone) to improve cardiac output and organ perfusion before aggressive diuresis or vasodilation can be tolerated. [11]

Question 7: The "Flash" Intervention

A patient with hypertensive AHF (BP 210/110) remains severely dyspneic despite 100% O2 and IV Furosemide. Which intervention has the most rapid effect on reducing pulmonary congestion in this specific phenotype?

• A) IV Digoxin loading
• B) IV Morphine 5mg
• C) Non-invasive ventilation (CPAP)
• D) Oral Amlodipine 10mg
• E) IV Heparin bolus
• Answer: C. CPAP works within minutes by increasing intrathoracic pressure, which reduces venous return (preload) and reduces the effort required to breathe. It is the most effective early intervention for hypertensive pulmonary edema. [10]

Question 8: The Cardiogenic Shock Marker

Which of the following parameters, often measured via a Pulmonary Artery Catheter, is the strongest predictor of mortality in patients with cardiogenic shock?

• A) Pulmonary Capillary Wedge Pressure (PCWP)
• B) Mean Arterial Pressure (MAP)
• C) Cardiac Power Output (CPO)
• D) Central Venous Pressure (CVP)
• E) Systemic Vascular Resistance (SVR)
• Answer: C. Cardiac Power Output (CPO = MAP x CO / 451) is the strongest hemodynamic predictor of mortality in cardiogenic shock. A CPO less than 0.6 Watts is associated with a poor prognosis. [57]

Question 9: The Right Heart Failure Phenotype

A 50-year-old female presents with JVP to the angle of the jaw, massive ascites, and pitting edema to the mid-thigh. Her lungs are completely clear on auscultation. What is the most likely diagnosis?

• A) Acute Left Ventricular Failure (HFrEF)
• B) Isolated Right Heart Failure
• C) Flash Pulmonary Edema
• D) Acute Respiratory Distress Syndrome (ARDS)
• E) Cardiac Tamponade
• Answer: B. Isolated Right Heart Failure (e.g., from pulmonary hypertension or RV infarction) presents with signs of systemic venous congestion (high JVP, ascites, edema) but without signs of pulmonary congestion (clear lungs). [53]

Question 10: The Peripartum Algorithm

A 28-year-old female presents 3 weeks postpartum with new-onset AHF. Her LVEF is 25%. Which medication, in addition to standard heart failure therapy, has been shown to improve LV recovery in this condition?

• A) Bromocriptine
• B) Oxytocin
• C) Progesterone
• D) Prednisolone
• E) Magnesium Sulfate
• Answer: A. Bromocriptine (an agonist of dopamine receptors that inhibits prolactin) has been shown in small trials and the ESC PPCM registry to improve LV recovery by blocking the production of the cardiotoxic 16kDa prolactin fragment. [48]

---

17. References

1. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. [PMID: 34447992]
2. Ambrosy AP, et al. The global health and economic burden of hospitalizations for heart failure. J Am Coll Cardiol. 2014. [PMID: 24703920]
3. Nieminen MS, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J. 2005. [PMID: 15681577]
4. Mebazaa A, et al. Recommendations on pre-hospital & early hospital management in acute heart failure. Eur Heart J. 2015. [PMID: 25995431]
5. Nohria A, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003. [PMID: 12727447]
6. Gandhi SK, et al. Pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001. [PMID: 11136709]
7. Felker GM, et al. Diuretic strategies in patients with acute decompensated heart failure (DOSE). N Engl J Med. 2011. [PMID: 21366472]
8. Klein L, et al. Admission hyponatremia is associated with adverse outcomes in AHF. Circ Heart Fail. 2008. [PMID: 20031544]
9. Januzzi JL, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol. 2005. [PMID: 15842936]
10. Gray A, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema (3CPO). N Engl J Med. 2008. [PMID: 18614508]
11. Hochman JS, et al. Cardiogenic shock. N Engl J Med. 2017. [PMID: 28249871]
12. Bussmann WD, et al. Nitroglycerin in acute heart failure. Am J Cardiol. 1980.
13. Dunlay SM, et al. Epidemiology of Heart Failure with Preserved Ejection Fraction. Nat Rev Cardiol. 2017. [PMID: 28492288]
14. Krumholz HM, et al. Readmission after hospitalization for heart failure. Arch Intern Med. 2000. [PMID: 11046410]
15. Sanz-Sanchez J, et al. Atrial fibrillation and heart failure. Rev Esp Cardiol. 2016.
16. Schrier RW. Pathogenesis of sodium and water retention in heart failure. N Engl J Med. 1988. [PMID: 3283556]
17. Cohn JN, et al. Plasma norepinephrine as a guide to prognosis in CHF. N Engl J Med. 1984. [PMID: 6749185]
18. Ronco C, et al. Cardio-renal syndromes. J Am Coll Cardiol. 2008. [PMID: 18984288]
19. Knudsen AS, et al. Value of chest radiography in acute heart failure. Radiology. 2010.
20. Wang CS, et al. Does this patient have heart failure? JAMA. 2005. [PMID: 16234501]
21. Kociol RD, et al. Troponin elevation in patients hospitalized with heart failure. Circ Heart Fail. 2010. [PMID: 20100995]
22. Uriel N, et al. Mechanical Circulatory Support in Cardiogenic Shock. J Am Coll Cardiol. 2017. [PMID: 28449774]
23. Piazza G, et al. Heart failure and venous thromboembolism. Circulation. 2011. [PMID: 22105199]
24. Velazquez EJ, et al. Angiotensin-Neprilysin Inhibition in AHF (PIONEER-HF). N Engl J Med. 2019. [PMID: 30423390]
25. McMurray JJV, et al. Dapagliflozin in Patients with HFrEF (DAPA-HF). N Engl J Med. 2019. [PMID: 31535768]
26. Packer M, et al. Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med. 2020. [PMID: 32865377]
27. Al Deeb M, et al. POCUS for the diagnosis of acute cardiogenic pulmonary edema. Ann Emerg Med. 2014. [PMID: 24332429]
28. Fonarow GC, et al. Risk stratification for in-hospital mortality in AHF. JAMA. 2005. [PMID: 15687312]
29. Yancy CW, et al. Heart failure in African Americans. J Am Coll Cardiol. 2005. [PMID: 16226162]
30. Mann DL. Basic mechanisms of disease progression in heart failure. Eur Heart J. 2005.
31. Levin ER, et al. Natriuretic peptides. N Engl J Med. 1998. [PMID: 9682046]
32. Marti CN, et al. Endothelial dysfunction, inflammation, and heart failure. Eur Heart J. 2012.
33. Januzzi JL, et al. ST2 and Galectin-3. J Am Coll Cardiol. 2013.
34. Parshall MB, et al. Update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012.
35. Badgett RG, et al. Can the physical examination diagnose left ventricular dysfunction? JAMA. 1997. [PMID: 9168295]
36. Thibodeau JT, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014. [PMID: 24622144]
37. Voors AA, et al. Empagliflozin in patients hospitalized with acute heart failure (EMPULSE). Nat Med. 2022. [PMID: 35228754]
38. Costanzo MR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure (UNLOAD). J Am Coll Cardiol. 2007. [PMID: 17291828]
39. Wachter R, et al. Initiation of sacubitril/valsartan in hospitalised patients with heart failure (TRANSITION). Eur J Heart Fail. 2019. [PMID: 30907481]
40. Teerlink JR, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF). Lancet. 2013. [PMID: 23141184]
41. Packer M, et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF). N Engl J Med. 2017. [PMID: 28402745]
42. Lee DS, et al. Effect of Self-Care Support on 30-Day Hospitalization in Patients With Acute Heart Failure (COACH). JAMA. 2023. [PMID: 36814247]
43. Mullens W, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR). N Engl J Med. 2022. [PMID: 36037145]
44. Trullàs JC, et al. Hydrochlorothiazide in Acute Heart Failure (CLOROTIC). Eur Heart J. 2023. [PMID: 36440938]
45. Testani JM, et al. Impact of diuretic-induced weight loss on kidney function and outcomes in AHF. Circulation. 2011. [PMID: 21670229]
46. Sliwa K, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy. Eur Heart J. 2010. [PMID: 20639277]
47. Hilfiker-Kleiner D, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007. [PMID: 17289570]
48. Sliwa K, et al. Evaluation of bromocriptine in the treatment of PPCM: a randomized, controlled trial. Circulation. 2017. [PMID: 28438806]
49. Damman K, et al. Clinical and prognostic associations of frailty in heart failure. J Am Coll Cardiol. 2014. [PMID: 25012117]
50. Qaddura A, et al. Hospital-at-home for acute heart failure: a systematic review. JACC Heart Fail. 2021. [PMID: 34193361]
51. Horwich TB, et al. The obesity paradox in heart failure: is it real? J Am Coll Cardiol. 2013. [PMID: 24050805]
52. Madamanchi C, et al. Obesity and natriuretic peptides in heart failure. Heart Fail Rev. 2014. [PMID: 24395610]
53. Konstam MA, et al. Evaluation and management of right-sided heart failure: a scientific statement from the AHA. Circulation. 2018. [PMID: 29650544]
54. Rao P, et al. VA-ECMO and LV unloading. J Am Coll Cardiol. 2018. [PMID: 30139445]
55. Thiele H, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock (IABP-SHOCK II). N Engl J Med. 2012. [PMID: 22924681]
56. Binanay C, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE). JAMA. 2005. [PMID: 16204662]
57. Fincke R, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock. J Am Coll Cardiol. 2004. [PMID: 15337173]
58. Chen HH, et al. Effect of low-dose dopamine or low-dose nesiritide on renal function in acute heart failure (ROSE-AHF). JAMA. 2013. [PMID: 24240656]
59. Bart BA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome (CARRESS-HF). N Engl J Med. 2012. [PMID: 23131078]
60. Megalla S, et al. Congestive hepatopathy and heart failure outcomes. Am J Cardiol. 2011. [PMID: 21723821]
61. Sandek A, et al. The gut and heart failure. J Am Coll Cardiol. 2007. [PMID: 17825708]
62. Li SZ, et al. Ventricular arrhythmias in acute heart failure. Heart. 2018. [PMID: 29535171]
63. Dunlay SM, et al. Palliative care in heart failure. J Am Coll Cardiol. 2015. [PMID: 26315532]
64. Johnson MJ, et al. Opioids for chronic breathlessness. Cochrane Database Syst Rev. 2016. [PMID: 27031122]
65. Goldstein NE, et al. Deactivation of ICDs at the end of life. Ann Intern Med. 2004. [PMID: 15466768]
66. Adams KF, et al. Clinical predictors of in-hospital mortality in ADHF: results from the ADHERE registry. J Am Coll Cardiol. 2005. [PMID: 15862852]
67. Voors AA, et al. Optimization of medical therapy in heart failure: the BIOSTAT-CHF study. Eur J Heart Fail. 2017. [PMID: 28414164]
68. Bettencourt P, et al. NT-proBNP and prognosis after hospital discharge in AHF. Circulation. 2004. [PMID: 15557371]
69. Watkins DA, et al. Global burden of rheumatic heart disease. N Engl J Med. 2017. [PMID: 28834377]
70. Nunes MCP, et al. Chagas cardiomyopathy: an update of current knowledge and future prospects. Global Heart. 2013. [PMID: 24391263]

---

Last Updated: 2026-01-04 | MedVellum Editorial Team | Status: Gold Standard (V4)

---

Last Updated: 2026-01-04 | MedVellum Editorial Team | Status: Gold Standard (V4)